Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Retained Earnings (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Retained Earnings data on record, last reported at -$667.5 million in Q4 2025.

  • For Q4 2025, Retained Earnings fell 178854.42% year-over-year to -$667.5 million; the TTM value through Dec 2025 reached -$667.5 million, down 178854.42%, while the annual FY2025 figure was -$667.5 million, 178854.42% down from the prior year.
  • Retained Earnings reached -$667.5 million in Q4 2025 per MIRM's latest filing, down from $37000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $920000.0 in Q3 2024 and bottomed at -$667.5 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$290.1 million, with a median of -$293.8 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: plummeted 5939783.33% in 2022, then skyrocketed 100.18% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$35000.0 in 2021, then crashed by 520.0% to -$217000.0 in 2022, then crashed by 256231.34% to -$556.2 million in 2023, then soared by 99.93% to -$373000.0 in 2024, then crashed by 178854.42% to -$667.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$667.5 million in Q4 2025, $37000.0 in Q3 2025, and -$664.7 million in Q2 2025.